DRREDDY
Dr. Reddy's Laboratories Limited (DRREDDY) Stock Analysis
Dr. Reddy's Laboratories Limited is a major Indian pharmaceutical company with global generics and APIs. It develops and markets medicines in regulated and emerging markets worldwide. Scale in biosimilars and complex generics supports its international footprint. The company is listed on Indian stock exchanges and is headquartered in India.
Healthcare › Drug Manufacturers - Specialty & Generic
₹1,197.00
-0.76% 1W | -3.40% 52W
Market Cap
99.7k CR
P/E Ratio
30.1
52W High
₹1414.9
52W Low
₹1101
Div. Yield
0.68%
Beta
0.2
50 DMA
₹1181
200 DMA
₹1245.1
Profit Margin
10%
Inst. Own.
53%
🚀 BREAKOUT
🚀 BREAKOUT
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,758 | 6,903 | 7,237 | 7,114 | 7,696 | 8,038 | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 | 7,546 | 8,100 |
| Expenses | 4,696 | 4,894 | 5,214 | 5,283 | 5,566 | 5,962 | 6,108 | 6,530 | 6,398 | 6,818 | 6,866 | 7,164 | 7,240 |
| Operating Profit | 2,062 | 2,008 | 2,023 | 1,831 | 2,130 | 2,076 | 2,273 | 1,998 | 2,174 | 2,010 | 1,888 | 382 | 860 |
| OPM % | 31% | 29% | 28% | 26% | 28% | 26% | 27% | 23% | 25% | 23% | 22% | 5% | 11% |
| Other Income | 178 | 319 | 219 | 201 | 193 | 314 | 154 | 528 | 290 | 330 | 271 | 480 | 356 |
| Interest | 37 | 35 | 39 | 59 | 60 | 76 | 82 | 66 | 83 | 91 | 94 | 106 | 126 |
| Depreciation | 353 | 376 | 374 | 368 | 381 | 397 | 471 | 455 | 476 | 505 | 521 | 557 | 537 |
| Profit before tax | 1,850 | 1,917 | 1,829 | 1,605 | 1,883 | 1,917 | 1,874 | 2,005 | 1,905 | 1,745 | 1,543 | 200 | 553 |
| Tax % | 24% | 23% | 24% | 18% | 26% | 30% | 25% | 21% | 26% | 23% | 23% | -11% | 21% |
| Net Profit | 1,405 | 1,482 | 1,381 | 1,310 | 1,392 | 1,342 | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 | 221 | 436 |
| EPS in Rs | 16.87 | 17.77 | 16.56 | 15.70 | 16.69 | 15.05 | 16.94 | 19.09 | 16.99 | 16.14 | 14.50 | 2.65 | 5.32 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15,023 | 15,568 | 14,196 | 14,281 | 15,448 | 17,517 | 19,048 | 21,545 | 24,670 | 28,011 | 32,644 | 33,700 | 33,228 |
| Expenses | 11,515 | 11,983 | 11,724 | 11,930 | 12,270 | 15,040 | 15,173 | 17,778 | 18,200 | 20,078 | 24,097 | 27,247 | 28,088 |
| Operating Profit | 3,508 | 3,585 | 2,472 | 2,351 | 3,178 | 2,477 | 3,874 | 3,768 | 6,470 | 7,933 | 8,547 | 6,454 | 5,140 |
| OPM % | 23% | 23% | 17% | 16% | 21% | 14% | 20% | 17% | 26% | 28% | 26% | 19% | 15% |
| Other Income | 260 | 295 | 172 | 155 | 381 | 670 | 335 | 555 | 971 | 909 | 1,119 | 1,372 | 1,437 |
| Interest | 108 | 83 | 63 | 79 | 89 | 98 | 97 | 96 | 143 | 171 | 283 | 374 | 416 |
| Depreciation | 760 | 939 | 1,027 | 1,077 | 1,135 | 1,163 | 1,229 | 1,165 | 1,250 | 1,470 | 1,704 | 2,059 | 2,119 |
| Profit before tax | 2,900 | 2,859 | 1,554 | 1,350 | 2,336 | 1,886 | 2,884 | 3,061 | 6,048 | 7,201 | 7,680 | 5,393 | 4,041 |
| Tax % | 19% | 26% | 19% | 32% | 17% | -7% | 32% | 29% | 25% | 23% | 25% | 23% | |
| Net Profit | 2,336 | 2,131 | 1,292 | 947 | 1,950 | 2,026 | 1,952 | 2,182 | 4,507 | 5,578 | 5,725 | 4,158 | 3,183 |
| EPS in Rs | 27.43 | 24.98 | 15.59 | 11.41 | 23.49 | 24.38 | 23.47 | 26.23 | 54.14 | 66.87 | 67.77 | 50.27 | 38.61 |
| Dividend Payout % | 15% | 16% | 26% | 35% | 17% | 21% | 21% | 23% | 15% | 12% | 12% | 16% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 11.0% | 12.0% | 8.0% |
| Profit CAGR | -4.0% | 15.0% | 7.0% |
Shareholding Pattern
Promoters26.64%
FIIs25.33%
DIIs26.73%
Public21.04%
Promoters26.64%
FIIs24.69%
DIIs27.99%
Public20.45%
Promoters26.64%
FIIs22.34%
DIIs30.44%
Public20.33%
Promoters26.63%
FIIs21.14%
DIIs30.72%
Public21.27%
Promoters26.63%
FIIs20.67%
DIIs31.75%
Public20.76%
Promoters26.69%
FIIs27.25%
DIIs23.05%
Public22.78%
Promoters26.65%
FIIs29.13%
DIIs18.31%
Public25.73%
Promoters26.64%
FIIs25.75%
DIIs25.63%
Public21.69%
Promoters26.63%
FIIs21.14%
DIIs30.72%
Public21.27%
Promoters26.63%
FIIs20.67%
DIIs31.75%
Public20.76%
DRREDDY
Holdings Analysis
Key strengths & risk signals
63
Overall
56
Fundamental
71
Technical
Risks (4)
Cannot calculate PEG - insufficient growth data.
WEAK YEAR! Stock declined 3.4% in the last year.
LOWER HALF! Trading at 30.6% of 52W range - weakness visible.
WEAK MOMENTUM! Limited price growth - -0.8% (1 week), 4.5% (1 month), -3.8% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BREAKOUT! Stock has broken above resistance levels with momentum.
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 2,035,980 vs down days: 1,588,521. Ratio: 1.28x
Fundamental & Technical Analysis
63Overall
56Fundamental
71Technical
Fundamental Breakdown
Growth Quality
13/30
Revenue CAGR: 11.0% (GOOD, 11/15). Profit CAGR: -1.7% (DECLINING, 2/15).
Profit Margin
5/10
LOW MARGIN! 10.0% profit margin - thin profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.68% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.14 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 24.11% public ownership - balanced ownership structure.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
5/10
BEARISH TREND! 50-day average (1181.0) is below 200-day average (1245.1) - negative signal.
Price Position
6/10
MIXED POSITION! Current price (1197.0) above 50-day but below 200-day.
Trend Pattern
20/20
BREAKOUT! Stock has broken above resistance levels with momentum.
52W Performance
3/10
WEAK YEAR! Stock declined 3.4% in the last year.
Volume Sentiment
25/30
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 2,035,980 vs down days: 1,588,521. Ratio: 1.28x
RSI
3/5
NEUTRAL! RSI at 50.7 - balanced momentum.
52W Range
2/5
LOWER HALF! Trading at 30.6% of 52W range - weakness visible.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -0.8% (1 week), 4.5% (1 month), -3.8% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.20 - stable stock, less market risk.
DRREDDY
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q4FY262026-07-28 | Concall PDF | |
| Q2FY262026-01-27 | Concall PDF | |
| Q1FY262025-10-30 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DRREDDY | ₹1,197.00 | 30.1 | 10.0% | 11.0% | -1.7% | -3.4% | 63 | BREAKOUT | -68.7% | +100.8% | -5.6% | +7.4% |
| MANKIND | ₹2,368.50 | 47.9 | 13.9% | 17.7% | 14.3% | -3.2% | 70 | APPROACHING SUPPORT | +29.6% | +2.5% | +12.9% | +17.1% |
| AUROPHARMA | ₹1,693.00 | 26.5 | 10.6% | 10.7% | 22.1% | +45.5% | 81 | APPROACHING RESISTANCE | +25.2% | +12.1% | +16.9% | +4.0% |
| CIPLA | ₹1,301.00 | 31.2 | 12.0% | 7.2% | 11.5% | -16.3% | 60 | APPROACHING SUPPORT | -39.2% | +42.3% | +3.5% | +9.5% |
| LUPIN | ₹1,956.50 | 16.2 | 18.5% | 19.1% | 131.5% | -1.1% | 65 | BREAKDOWN | +16.1% | -3.1% | +33.3% | +11.2% |
| LAURUSLABS | ₹2,036.60 | 100.7 | 15.0% | 3.8% | 4.0% | +127.9% | 55 | CONSOLIDATING UP | +125.5% | +31.7% | +29.1% | +11.9% |
| ZYDUSLIFE | ₹1,117.50 | 24.9 | 15.8% | 16.5% | 37.0% | +15.9% | 75 | APPROACHING SUPPORT | -35.9% | -26.1% | +20.6% | +4.9% |
| GLENMARK | ₹2,293.00 | 34.6 | 10.1% | 13.5% | 66.1% | +17.7% | 69 | BREAKDOWN | +929.6% | +60.2% | +28.5% | +4.6% |
Data from TradeAlone · Updated daily
DRREDDY News
Dr. Reddy’s Laboratories Limited (drreddy) Q2fy27 Results: Earnings and Revenue Insights2026-10-07Dr. Reddy’s Laboratories Receives U.S. FDA Approval for Rituximab Biosimilar2026-08-01Dr. Reddy’s Laboratories Limited (NSE: DRREDDY) bounces from support, falls 6% intraday2026-07-09Dr. Reddy’s Laboratories Limited (drreddy) Launches First-to-market Bosutinib Tablets 400mg in the U.S.2026-06-13Dr. Reddy’s Laboratories Limited (NSE: Drreddy) to Ring the Closing Bell at NYSE2026-05-28Dr. Reddy’s Laboratories Limited Q4 & FY26 Results Update: Strong Financial Performance and Strategic Milestones2026-05-12
